Abstract: A curing resin composition that cures in two stages: photo cure and thermal cure, hardly contaminates a liquid or liquid crystals when in contact with, and provides high adhesive strength, particularly a curing composition that photocures sufficiently even when shadowed by TFT wires, a black matrix, etc. in photocuring; and a sealant, a sealant for ODF (one-drop-fill), and an LCD containing the curing resin composition. The curing resin composition contains (A) an oxime ester radical initiator represented by general formula (I), where symbols are as defined in the description, (B) a radical curing resin, (C) a latent epoxy curing agent, and (D) an epoxy resin.

Abstract: A method is disclosed for preparing compounds of Formula 1 by combining compounds of Formulae 2 and 3 and a sulfonyl chloride. Also disclosed are compounds of Formula 3, which are useful as starting materials for this method.

Abstract: Compositions including a conjugate of ?-difluoromethylornithine can be applied topically to reduce hair growth.

Abstract: A family of molecules is disclosed that inhibit matrix metalloprotease (MMP) activity, and particularly inhibit the activity of one or more of MMP-2, MMP-9, or MMP-13, while generally exhibiting little activity against MMP-1. A contemplated compound also exhibits little inhibition of the production of TNF. A contemplated compound is an &agr;-amino-&bgr;-sulfonyl carbocyclo, heterocyclo, aryl, or heteroaryl hydroxamic acid. Also disclosed are processes for preparing a contemplated compound and for treating a mammal having a condition associated with pathological matrix metalloprotease activity.

Abstract: This invention pertains to novel salt forms of trophenylethylene compound, such as 3-[4(1,2-diphenyl-but-1-enyl)-phenyl]-acrylic acid, as selective estrogen receptor modulators. This invention also provides methods for the treatment and/or prevention of breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.

Abstract: A method for preparing N,N-disubstituted hydroxylamine compounds represented by the formula (II): HO--N(R.sup.1)(R.sup.2) wherein R.sup.1 and R.sup.2 may be the same or different, and independently represent a substituted or unsubstituted alkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, which comprises the step of adding a rhenium catalyst and aqueous hydrogen peroxide to a mixture containing a secondary amine compound represented by the formula (I): HN(R.sup.1)(R.sup.2) wherein R.sup.1 and R.sup.2 have the same meanings as those defined above and a dehydrating agent.

Abstract: .alpha.-chloro-.alpha.-oximino-4-hydroxyacetophenone is prepared by reacting 4-hydroxyacetophenone with an alkyl nitrite and hydrogen chloride wherein the amount of hydrogen chloride is carefully controlled to limit the amount thereof to about 0.1 to 6 moles of hydrogen chloride per mole of 4-hydroxyacetophenone until at least one equivalent of the alkyl nitrite is reacted. Subsequent to the reaction of the one equivalent of alkyl nitrite, at least 1 mole of hydrogen chloride per mole of initially charged 4-hydroxyacetophenone is added to the reaction medium.